Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy

Journal of International Medical Research

Volumn 25, Issue 3, 1997, Pages 127-134

  Takemasa, A ^a   Yorioka, N ^a   Yamakido, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaemia; Continuous ambulatory peritoneal dialysis; Erythropoietin; Fever; Influenza like syndrome; Interleukin 1 ; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 1BETA; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL;

EID: 0030958992     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500302     Document Type: Article

References (19)

1. Casati S, Passerini P, Campise MR, et al: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. BMJ 1987; 295: 1017-1020.
2. Grützmacher P, Bergmann M, Weinreich T, et al: Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol 1988; 66: 104-113.
3. Eschbach JW, Egrie JC, Downing MR, et al: The safety of epoetin-alpha: results of clinical trials in the United States. Contrib Nephrol 1991; 88: 72-80.
4. Takemasa A, Yorioka N, Ito T, et al: Recombinant human erythropoietin increases interleukin-1β production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy. (letter) Nephron 1994; 67: 245-247.
5. Takemasa A, Yorioka N, Yamakido M: Stimulation of interleukin-1β production may be involved in unresponsiveness to erythropoietin therapy. Int J Artif Organs 1996; 19: 633-637.
6. Schooley JC, Kullgren B, Allison AC: Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67: 11-17.
7. Johnson CS, Keckler DJ, Topper MI, et al: In vivo haematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678-683.
8. Akahane K, Hosoi T, Urabe A, et al: Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Cloning 1987; 5: 16-26.
9. Blick M, Sherwin SA, Rosenblum M, et al: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-2989.
10. Johnson CS, Chang MJ, Furmanski P: In vivo hematopoietic effects of tumor necrosis factor-α in normal and erythroleukemic mice: characterization and therapeutic applications. Blood 1988; 72: 1875-1883.
11. Johnson RA, Waddelow TA, Caro J, et al: Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130-138.
12. Clibon U, Bonewald L, Caro J, et al: Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. Exp Hematol 1990; 18: 438-441.
13. Saper CB, Breder CD: The neurologic basis of fever. N Engl J Med 1994; 330: 1880-1886.
14. Takeuchi M, Inoue N, Strickland TW, et al: Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1989; 86: 7819-7822.
15. 125I-KRN5702 after a single intravenous dose in rats. Clin Report 1988; 22: 415-434. In Japanese.
16. Kimata H, Yoshida A, Ishioka C, et al: Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 1991; 85: 151-156.
17. Rich IN, Kubanek B: Release of erythropoietin from macrophages mediated by phagocytosis of crystalline silica. J Reticuloendothelial Soc 1982; 31: 17-30.
18. Goy A, Belanger C, Casadevall N, et al: High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993; 84: 232-237.
19. Jelkmann W, Fandrey J, Pagel H: Effects of inflammatory cytokines on the production of erythropoietin. In: Pathophysiology and Pharmacology of Erythropoietin (Pagel H, Weiss C, Jelkmann W, eds). Berlin: Springer, 1992; pp 263-269.